About this article Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine (NEJM) (Mar 2021) Clinical Recommendations for the Management of Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists Journal of Clinical Medicine (Dec 2022) Notes:Article published
Currently, Parkinsons has no cure, but there are treatment options for individuals affected
A large retrospective cohort study published in JAMA Oncology evaluated more than 86,000 adults with obesity and found that individuals taking GLP-1 receptor agonists experienced a 17% lower overall risk of developing 13 out of 14 obesity-associated cancers compared with non-users, including a: 25% reduction in endometrial cancer
As a result there is a selective enrichment in red blood cells that, despite being genetically G6PD deficient, have relatively higher levels of G6PD
Insurance verification is part of this process
Unlike older weight loss medications, tirzepatide targets both GLP-1 and GIP receptors simultaneously, reducing appetite and slowing digestion, so you feel full longer
